EQT Life Sciences to exit minority stake in Tubulis via sale to Gilead Sciences for up to USD 5.0 billion

Gilead Sciences has entered into a definitive agreement to acquire Tubulis, a private Germany-based, clinical-stage biotechnology company EQT Life Sciences led the Series B2 financing of Tubulis in March 2024, and has since suppEQTorted the Company at board level in its growth to a...